Skip to results
Modify your search
NARROW
1-19 of 19
Authors: Percy Ivy
Journal Article
EDITOR'S CHOICE
Expanding access to early phase trials: the CATCH-UP.2020 experience Open Access
JNCI Cancer Spectrum, Volume 7, Issue 1, February 2023, pkac087, https://doi.org/10.1093/jncics/pkac087
Published: 16 December 2022
Journal Article
CTNI-50. A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB/OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: UPDATED RESULTS Free
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii83, https://doi.org/10.1093/neuonc/noac209.315
Published: 14 November 2022
Journal Article
Implementing Modernized Eligibility Criteria in US National Cancer Institute Clinical Trials Free
JNCI: Journal of the National Cancer Institute, Volume 114, Issue 11, November 2022, Pages 1437–1440, https://doi.org/10.1093/jnci/djac152
Published: 01 September 2022
Journal Article
Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute Free
The Oncologist, Volume 26, Issue 10, October 2021, Pages e1883–e1886, https://doi.org/10.1002/onco.13941
Published: 20 September 2021
Journal Article
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation Open Access
The Oncologist, Volume 26, Issue 7, July 2021, Pages e1104–e1109, https://doi.org/10.1002/onco.13758
Published: 05 May 2021
Journal Article
EDITOR'S CHOICE
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study Free
JNCI: Journal of the National Cancer Institute, Volume 113, Issue 1, January 2021, Pages 27–37, https://doi.org/10.1093/jnci/djaa061
Published: 27 April 2020
Journal Article
ACTR-61. A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA Free
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Page vi27, https://doi.org/10.1093/neuonc/noz175.103
Published: 11 November 2019
Journal Article
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer Free
The Oncologist, Volume 24, Issue 9, September 2019, Pages 1149–e807, https://doi.org/10.1634/theoncologist.2019-0331
Published: 31 May 2019
Journal Article
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology Open Access
JNCI: Journal of the National Cancer Institute, Volume 111, Issue 2, February 2019, Pages 118–128, https://doi.org/10.1093/jnci/djy196
Published: 17 December 2018
Journal Article
Editorial: Tissue Acquisition in Clinical Trials—Essential for Progress Free
JNCI: Journal of the National Cancer Institute, Volume 109, Issue 4, April 2017, djx003, https://doi.org/10.1093/jnci/djx003
Published: 09 March 2017
Journal Article
Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute Free
JNCI: Journal of the National Cancer Institute, Volume 108, Issue 3, March 2016, djv335, https://doi.org/10.1093/jnci/djv335
Published: 09 November 2015
Journal Article
ATNT-17EVALUATION OF THE SAFETY AND BENEFIT OF PHASE I ONCOLOGY TRIALS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMORS Free
Neuro-Oncology, Volume 17, Issue suppl_5, November 2015, Page v14, https://doi.org/10.1093/neuonc/nov205.17
Published: 09 November 2015
Journal Article
INCREASED PERFUSION DUE TO VASCULAR NORMALIZATION IMPROVES OXYGENATION AND SURVIVAL IN GLIOBLASTOMA PATIENTS TREATED WITH CEDIRANIB WITH OR WITHOUT CHEMORADIATION Get access
Neuro-Oncology, Volume 16, Issue suppl_3, July 2014, Page iii12, https://doi.org/10.1093/neuonc/nou206.42
Published: 01 July 2014
Journal Article
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma Get access
Neuro-Oncology, Volume 15, Issue 8, August 2013, Pages 1079–1087, https://doi.org/10.1093/neuonc/not082
Published: 01 August 2013
Journal Article
Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials Get access
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 24, 19 December 2012, Pages 1860–1866, https://doi.org/10.1093/jnci/djs439
Published: 19 November 2012
Journal Article
A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium Free
The Oncologist, Volume 15, Issue 8, August 2010, Pages 810–818, https://doi.org/10.1634/theoncologist.2010-0081
Published: 03 August 2010
Journal Article
Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors Get access
JNCI: Journal of the National Cancer Institute, Volume 102, Issue 9, 5 May 2010, Pages 596–604, https://doi.org/10.1093/jnci/djq091
Published: 05 May 2010
Journal Article
Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I study Get access
Neuro-Oncology, Volume 10, Issue 5, October 2008, Pages 752–758, https://doi.org/10.1215/15228517-2008-043
Published: 01 October 2008
Journal Article
Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G 2 Get access
JNCI: Journal of the National Cancer Institute, Volume 96, Issue 20, 20 October 2004, Pages 1557–1559, https://doi.org/10.1093/jnci/djh270
Published: 20 October 2004
